Solvay reduces 2010 pharma sales forecast
Belgium drugs, chemicals and plastics group Solvay, as a result of a "non-approvable" letter from the US Food and Drug Administration for it schizophrenia drug bifeprunox being developed with Wyeth (Marketletter August 20), has reduced the 2010 sales forecast for its pharmaceutical business to 3.2 billion euros ($4.51 billion), from a previous projection of 3.5 billion euros and compared with 2.6 billion euros for 2006. Speaking to investment analysts, the firm also said that the FDA has delayed the decision date for its artrial fibrillation drug Pulzium (tedisamil) by three months to January 19, 2008.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze